EMAIL THIS PAGE TO A FRIEND

Cellular and molecular life sciences : CMLS

The ether lipid precursor hexadecylglycerol protects against Shiga toxins.


PMID 24740796

Abstract

Shiga toxin-producing Escherichia coli bacteria cause hemorrhagic colitis and hemolytic uremic syndrome in humans. Currently, only supportive treatment is available for diagnosed patients. We show here that 24-h pretreatment with an ether lipid precursor, the alkylglycerol sn-1-O-hexadecylglycerol (HG), protects HEp-2 cells against Shiga toxin and Shiga toxin 2. Also the endothelial cell lines HMEC-1 and HBMEC are protected against Shiga toxins after HG pretreatment. In contrast, the corresponding acylglycerol, DL-α-palmitin, has no effect on Shiga toxicity. Although HG treatment provides a strong protection (~30 times higher IC₅₀) against Shiga toxin, only a moderate reduction in toxin binding was observed, suggesting that retrograde transport of the toxin from the plasma membrane to the cytosol is perturbed. Furthermore, endocytosis of Shiga toxin and retrograde sorting from endosomes to the Golgi apparatus remain intact, but transport from the Golgi to the endoplasmic reticulum is inhibited by HG treatment. As previously described, HG reduces the total level of all quantified glycosphingolipids to 50-70% of control, including the Shiga toxin receptor globotriaosylceramide (Gb3), in HEp-2 cells. In accordance with this, we find that interfering with Gb3 biosynthesis by siRNA-mediated knockdown of Gb3 synthase for 24 h causes a similar cytotoxic protection and only a moderate reduction in toxin binding (to 70% of control cells). Alkylglycerols, including HG, have been administered to humans for investigation of therapeutic roles in disorders where ether lipid biosynthesis is deficient, as well as in cancer therapy. Further studies may reveal if HG can also have a therapeutic potential in Shiga toxin-producing E. coli infections.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

C7617
Anti-Calnexin antibody, Mouse monoclonal, clone TO-5, purified from hybridoma cell culture
L7875
DL-Leucine, ≥99% (HPLC)
C6H13NO2
L0375000
Leucine, European Pharmacopoeia (EP) Reference Standard
C6H13NO2
EHU014711 MISSION® esiRNA, esiRNA targeting human A4GALT (esiRNA1)
EMU010761 MISSION® esiRNA, esiRNA targeting mouse A4galt (esiRNA1)
SAB5300526
Monoclonal Anti-CANX antibody produced in mouse, clone 3H4A7, ascites fluid
SAB1403056
Monoclonal Anti-FLOT1 antibody produced in mouse, clone 4A1, ascites fluid
545023
Ruthenium, powder, 99.99% trace metals basis
Ru
209694
Ruthenium, powder, −200 mesh, 99.9% trace metals basis
Ru
267406
Ruthenium, sponge, −100 mesh, 99.9% trace metals basis
Ru
GF40738260
Ruthenium, Ruthenium, foil, 6x6mm, thickness 1.0mm, 99.9%
Ru
GF83525193
Ruthenium, Ruthenium, bar, 25mm x 2mm x 2mm, 99.9%
Ru
GF50816998
Ruthenium, Ruthenium, bar, 50mm x 2mm x 2mm, 99.9%
Ru
GF07844249
Ruthenium, Ruthenium, foil, 10x10mm, thickness 1.0mm, 99.9%
Ru
GF86442183
Ruthenium, Ruthenium, rod, 12.7mm, diameter 12.7mm, 99.9%
Ru
GF60948658
Ruthenium, Ruthenium, microfoil, disks, 10mm, thinness 0.025μm, specific density 30.5μg/cm2, permanent mylar 3.5μm support, 99.9%
Ru
GF01141333
Ruthenium, Ruthenium, microfoil, disks, 10mm, thinness 0.1μm, specific density 122μg/cm2, permanent mylar 3.5μm support, 99.9%
Ru
GF85328523
Ruthenium, Ruthenium, pellets, 2.5g, max. size 10mm, 99.9%
Ru
GF65001440
Ruthenium, Ruthenium, pellets, 5g, max. size 10mm, 99.9%
Ru
GF58059120
Ruthenium, Ruthenium, foil, 25x25mm, thickness 1.0mm, 99.9%
Ru
326712
Ruthenium black
Ru
206180
Ruthenium on carbon, extent of labeling: 5 wt. % loading
Ru